Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of two mesothelioma cell lines (MPP89 and REN), and of HMC-TERT non tumoral mesothelial cells
miRNA profile analysis of two mesothelioma cell lines (MPP89 and REN), and of HMC-TERT non tumoral mesothelial cells
ORGANISM(S): Homo sapiens 
2008-10-09 | E-MEXP-1699 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human mesothelioma cells MPP-89 REN compared to mesothelial cells HMC-TERT
gene expression profile of mesothelioma cells (MPP-89; REN) compared to mesothelial cells (HMC-TERT)
ORGANISM(S): Homo sapiens 
2008-10-09 | E-MEXP-1701 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human mesothelioma cells (MPP-89, REN) compared to mesothelial cells (HMC-TERT)
gene expression profiles of mesothelioma cells (MPP-89, REN) compared to mesothelial cells (HMC-TERT)
ORGANISM(S): Homo sapiens 
2008-10-09 | E-MEXP-1700 | biostudies-arrayexpress
TranscriptomicsReduced expression of RhoE promotes ROCK-dependent invasion in transformed human fibroblasts
Cen3tel cells, obtained by telomerase immortalization of human fibroblasts, gradually underwent neoplastic transformation and became metastatic in immunocompromised mice. Neoplastic transformation was associated with a change in cell morphology (from fibroblastic to polygonal). Tumorigenic cells acq...
ORGANISM(S): Homo sapiens 
2011-04-20 | E-GEOD-15742 | biostudies-arrayexpress
Genomicsena-DATASET-CRUK-LRI-05-08-2014-14:10:54:243-46 - samples
Van Hippel-Lindau syndrome multi-region exome sequencing of two patients
EGAD00001000973 | EGA
GenomicsVon Hippel-Lindau syndrome multi-region exome sequencing project from two patients undertaken at Cancer Research UK's London Research Institute
Multi-region whole exome sequencing of tumours from patients with Von Hippel-Lindau syndrome reveals convergence of mutayional events upon the PI3L-AKT-mTOR signalling pathway.
EGAS00001000907 | EGA
TranscriptomicsHER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
HER2 targeting with trastuzumab has changed the prognosis of breast cancer patients carrying amplification and/or overexpression of this oncogene. Despite this progress, however, resistance to trastuzumab occurs in the vast majority of patients. Newer anti-HER2 therapies, like the dual tyrosine-kina...
ORGANISM(S): Homo sapiens 
2010-12-15 | E-GEOD-17630 | biostudies-arrayexpress
UnknownTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Not available
S-EPMC7576974 | biostudies-literature
Sort   by:  
 Page size